Patients with an SOD1-A4V mutation, which accounts for approximately half of all SOD1-linked ALS cases in North America, have a rapid progression of disease, with a mean disease duration of only 1.0 ± 0.4 years3, highlighting the urgency of the unmet need for therapeutic development. The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.